AFJK experienced severe financial deterioration with current assets collapsing 94.8% while current liabilities surged over 3000%, creating a critical liquidity crisis.
The company's financial position has deteriorated dramatically, with current assets falling from $581K to just $30K while current liabilities exploded from $25K to $817K, indicating potential solvency issues. The share count reduction from 9.0M to 6.1M shares suggests either share buybacks or a restructuring event, while the company maintains its SPAC status seeking acquisitions in biopharmaceutical sectors.
AFJK's balance sheet shows alarming deterioration with current assets plummeting 95% to just $30K while current liabilities skyrocketed over 3000% to $817K, creating an immediate liquidity crisis. Despite operating losses worsening significantly (-$28K to -$1.1M), net income paradoxically improved to $2.6M, suggesting non-operating gains that may not be sustainable. The overall financial picture signals severe distress for this SPAC, with stockholders' equity deepening into negative territory and total liabilities doubling, raising serious going concern questions.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current liabilities surged 3188.9% — significant near-term obligations; verify ability to meet short-term debt.
Net income grew 1389.1% — bottom-line growth signals improving overall business health.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Liabilities grew 110.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Current assets declined 94.8% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →